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aims and hypothesis: Hypoxic-ischemic encephalopathy (HIE) remains an important 
cause of death and disability in newborns. Mild therapeutic hypothermia (TH) is safe 
and effective; however, there are no tissue biomarkers available at the bedside to select 
babies for treatment. The aim of this study was to show that it is feasible to study plasma 
neurofilament light (NfL) levels from newborns and to evaluate their temporal course. 
Hypothesis: Raised plasma NFL protein levels from newborns who undergo TH after HIE 
are associated with abnormal MRI outcomes.
Methods: Between February 2014 and January 2016, term newborns with HIE treated 
with TH for 72 h had plasma samples taken at three time points: (i) after the infant had 
reached target temperature, (ii) prior to commencing rewarming, and (iii) after completing 
rewarming. Infants with mild HIE who did not receive TH had a single specimen taken. 
NfL protein was analyzed using an enzyme-linked immunosorbent assay.
results: Twenty-six newborns with moderate–severe HIE treated with TH were studied. 
Half of these had cerebral MRI predictive of an unfavorable outcome. Plasma NfL levels 
were significantly higher in the TH group with unfavorable outcome (median age 18 h) 
compared to levels from both the mild HIE group and TH group with favorable outcome 
(F = 25.83, p < 0.0001). Newborns who had MRIs predictive of unfavorable outcome 
had significantly higher NfL levels compared to those with favorable outcomes, at all 
three time points (mixed models, F = 27.63, p < 0.001). A cutoff NfL level >29 pg/mL at 
24 h is predictive of an unfavorable outcome [sensitivity 77%, specificity 69%, positive 
predictive value (PPV) 67%, negative predictive value (NPV) 72%] with increasing predic-
tive value until after rewarming (sensitivity 92%, specificity 92%, PPV 92%, NPV 86%).
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interpretation of research: Plasma NfL protein levels may be a useful biomarker of 
unfavorable MRI outcomes in newborns with moderate–severe HIE and may assist in 
selecting newborns for adjunctive neuroprotective interventions. Larger studies with NfL 
testing at earlier time points are required.
Keywords: neurofilament proteins, hypoxic-ischemic encephalopathy, therapeutic hypothermia, Mri imaging, 
neuroprotection, biomarkers
inTrODUcTiOn
Perinatal asphyxia in the newborn remains an important cause of 
death and of disability in survivors. The resulting brain dysfunc-
tion and neonatal encephalopathy occurs in up to 4 per 1,000 live 
births in western countries (1, 2).
Mild therapeutic hypothermia (TH) treatment started within 
6 h after birth, has been shown to be safe and effective in reducing 
death and disability, with numbers needed to treat (NNT) of 7–9 
(3, 4). However, many babies go on to have adverse outcomes 
despite TH (5, 6). At present, empirical criteria are used to select 
babies for TH (7). Various compounds have been studied in the 
plasma, urine, and cerebrospinal fluid (CSF) as potential early 
biomarkers of CNS injury (8). There are no established blood bio-
markers available to assist early cot side identification of babies 
most likely to benefit from neuroprotection. As a result, a number 
of babies with hypoxic-ischemic encephalopathy (HIE) who do 
not fulfill empirical criteria and who do not receive TH are noted 
to have adverse outcomes (9).
Neurofilaments, a group of intermediate sized filamentous 
proteins, are the most abundant cytoskeletal component, found 
predominantly in the myelinated axons of the central nervous 
system (10). They contribute to axonal volume and the radial 
diameter and hence are important for efficient transmission of 
action potentials. The neurofilament light (NfL) protein subunit 
is primarily expressed in large caliber myelinated axons.
When neurons are damaged, the NfL protein is released into 
the CSF and blood (10). An increased NfL protein level in CSF and 
blood is associated with the severity of neuropathology in adults 
with diseases including amyotrophic lateral sclerosis (ALS) (11), 
spinal cord injury (12), and multiple sclerosis (13). In asphyxiated 
newborns, neurofilament levels have been shown to be raised in 
CSF (14) and Toorell et al. (15) have recently reported raised levels 
in cord blood from asphyxiated newborns when compared to term 
controls. To date, there are no studies reporting the feasibility of 
studying plasma NfL levels in newborns with HIE who undergo TH 
and in the evaluation of their temporal course. We hypothesized that 
plasma NfL levels are significantly raised in newborns with cerebral 
MRI predictive of unfavorable neurodevelopmental outcomes.
If NfL is shown to be a reliable biomarker, then the selection 
of newborns for TH will be more effective with objective target-
ing of babies who will benefit most. The injury cascade affecting 
the newborn brain after hypoxia-ischemia continues for hours 
and days after the initial insult, with multiple mechanisms being 
implicated and hence various potential adjunctive neuroprotec-
tion targets could be considered (16). If reliable, NfL may prove 
to be a suitable biomarker of neuronal injury and useful for the 
evaluation of additional neuroprotective interventions.
MaTerials anD MeThODs
study Population
Between January 2014 and January 2016, newborns were 
recruited into the Brain Injury Biomarkers in Newborns study 
from five tertiary neonatal centers; the Royal London Hospital, 
Homerton University Hospital, Ashford and St. Peter’s Hospitals 
NHS Foundation Trust, University Hospital Southampton, and 
Norfolk and Norwich University Hospital. Babies were enrolled 
after written consent was obtained from the parents and this 
study had research ethics committee approval (REC reference: 
13/LO/17380).
Two categories of babies were included: (1) 11 consecutively 
recruited term newborns admitted to the neonatal units with 
acidosis and/or mild HIE who did not fulfill standard criteria for 
TH and were managed conservatively and (2) babies who fulfilled 
standard cooling criteria (UK TOBY Cooling Register Clinician’s 
Handbook) who underwent TH and had cerebral MR imaging. 
Of the latter group, the first 13 recruited with MR imaging pre-
dictive of favorable outcome and the first 13 with MR imaging 
predictive of unfavorable outcomes were included in the study. 
Exclusion criteria included death before an MRI was obtained 
(TH group), images degraded by significant motion artifact, 
major congenital anomaly, or a primary diagnosis of an inborn 
error of metabolism.
Blood from the babies with mild HIE who did not undergo 
TH was obtained at a single time point. Samples from babies who 
received TH were obtained at three time points in the first week 
after birth: (i) after the target temperature of 33–34°C was reached 
(S1), (ii) prior to rewarming (S2), and (iii) after rewarming was 
completed (S3).
Preparation and analysis of Plasma 
samples
Collected blood samples were transferred into spray-coated 
K2EDTA tubes (Fisher Scientific Ltd., Loughborough, UK), then 
centrifuged at 15,000 × g for 10 min to separate plasma, which 
was stored at −80°C until analysis.
A commercially available enzyme-linked immunosorbent 
assay (ELISA) (UD51001, IBL-International GmbH) was 
used to quantify NfL. Bovine NfL standards ranging from 0 
to 10,000  pg/mL and 100  µL of diluted samples from each 
newborn (50  µL of neat plasma sample diluted with 160  µL 
sample diluent) were run in duplicate, following the manu-
facturer’s instructions. The optical density of each sample was 
determined at a wavelength of 450  nm. NfL concentrations 
were calculated using the inverse formula: x  =  c(((a  −  d)/
Table 1 | Comparison of the clinical characteristics of the three groups of babies studied.
Mild
no therapeutic hypothermia (Th)
Mod-severe
Th favorable
Mod-severe
Th unfavorable
p-Value
n 11 13 13
Male 5/11 9/13 9/13 0.39
Birth weight (g) 3,360 (2,971, 3,987) 3,546 (3,045, 3,880) 3,440 (2,800, 3,770) 0.70
PMA 40 (39, 41.29) 39.57 (38.86, 41) 40.14 (38, 41) 0.73
10-min Apgar 9 (8,9) 6 (4,7) 5 (4,6) 0.001
Chest compressions 0/9 3/10 7/11 0.035
Resuscitation cardiac drugs 0/9 2/12 5/11 0.13
Worst pH in first hour 6.96 (6.91,7.03) 6.90 (6.71, 7.00) 6.87 (6.77,6.94) 0.27
Worst base deficit in first hour −15 (−12, −8) −17 (−13, −21) −20 (−18, −23) 0.14
Maternal pyrexia 2/10 0/12 0/12 0.22
Chorioamnionitis 0/9 0/13 0/12 0.52
Sentinel event 1/11 4/13 3/13 0.25
Meconium aspiration 0/10 1/13 2/12 0.41
Blood glucose (<2.6 mmol/l) 0/8 0/8 0/9 0.83
Positive blood culture 0/10 0/13 1/13 (CONS*) 0.38
Clinical seizures 0/10 8/13 12/13 <0.001
Anticonvulsants given 0/10 7/13 10/12 <0.001
Inotropes used 0/11 2/13 9/12 <0.001
Age at MRI scan (days) – 8 (7, 9) 9 (8, 12) 0.56
Data in brackets represent median interquartile range.
CONS*, coagulase negative staphylococci.
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(y − d)) − 1)1/b provided by the online ELISA software (http://
elisaanalysis.com). This study was carried out with three NfL 
ELISA plates from different batches at different times, to ensure 
the test was not affected by variability between plates. Each 
ELISA plate contained samples from all three groups and from 
different time points. Each plate was processed at a different 
time. The mean of the two results was reported. A coefficient 
of variation of up to 10% was accepted.
Outcomes
Infants who underwent TH had cerebral MR imaging. MRI 
was performed at local centers with conventional T1-weighted 
and T2-weighted sequences at 1.5  T. MR images were inde-
pendently rated by a neuroradiologist (JE) and a neonatologist 
with imaging expertise (OK) who were blinded to clinical 
information. All images were of sufficient quality to be report-
able by each rater. Patterns of MRI injury were classified 
into two groups using the system described by Rutherford 
et  al. (17), which has prognostic value in infants who have 
undergone TH. Infants with an unfavorable outcome had a 
severe pattern of injury including reversed or abnormal signal 
intensity bilaterally on T1- and/or T2-weighted sequences in 
the posterior limb of the internal capsule (PLIC); multifocal 
or widespread abnormal signal intensity in the basal ganglia 
and thalami (BGT); and severe widespread white matter 
(WM) lesions including infarction, hemorrhage and long T1 
and T2. Infants with MRIs predictive of a favorable outcome 
had either normal images or less severe patterns of injury that 
are associated with normal or only mildly abnormal neurode-
velopmental outcomes. Consensus was reached in cases of 
disagreement.
Infants who did not qualify for TH were classified as having a 
favorable outcome if they had a normal neurologic examination 
at 24 h of age and were discharged home on suck feeding. These 
infants did not have MR imaging.
statistical analysis
Statistical analysis was carried out using SPSS (version 22). 
Continuous variables between groups were compared using 
ANOVA and proportions were compared using Pearson’s chi-
square statistic. NfL levels for S1 were positively skewed and 
were log transformed prior to analysis with ANOVA. Receiver 
operated characteristics (ROC) curves were created comparing 
the mild HIE group with the TH unfavorable outcome group at 
S1 and also comparing the TH favorable with the unfavorable 
outcome group at all three time points S1, S2, and S3. For each 
ROC curve, a cutoff level was obtained where the sensitiv-
ity + specificity was at its maximum. All graphs and ROC were 
created using GraphPad Prism (version 6.0). p < 0.05 was used 
as the level of statistical significance.
resUlTs
The perinatal characteristics of the newborns studied are 
described in Table 1. Babies in the unfavorable outcome group 
were more likely to have had a lower 10-min Apgar score, and 
to have had chest compressions at resuscitation, anticonvulsants, 
and inotropic support.
Mri Outcome
The 26 babies who underwent TH all had MRI performed at a 
median age of 9 [interquartile range (IQR) 8, 11] days. There was no 
statistical difference in age at MRI between the 13 babies with MRI 
predictive of favorable outcome and the other 13 with MRI predic-
tive of unfavorable outcome (F = 0.89, p = 0.56) (Table 1). Of the 
13 infants with images predictive of unfavorable outcome, six had 
Table 2 | Patients arranged in descending rank order of neurofilament light levels at S3 in relation to MRI findings and neurological exam at discharge. The latter is 
classified primarily in terms of abnormality of tone.
s1  
(pg/ml)
s2  
(pg/ml)
s3  
(pg/ml)
age at  
peak (h)
electrical 
seizures 
(Y/n)
Plic bgT WM cortex composite 
Mri group
sentinel 
event 
(Y/n)
comment neurologic  
exam prior to 
discharge
1 2,506 2,255 4,698 100 Y Loss Severe Moderate Normal U N Severe, died
2 1,999 1,615 1,993 18 N Equivocal Normal Severe Moderate U Y Cord  
prolapse
Mild
3 0 189 1,626 124 Y Loss Severe Severe Severe U N Severe, died
4 70 423 1,014 114 N Loss Severe Mild Mild U Y Breech, head 
entrapment
Moderate,  
tube feeds
5 1,046 1,512 874 31 Y Normal Moderate Normal Normal U N Normal
6 516 n/a 849 96 N Equivocal Normal Severe Severe U Y Placental 
abruption
Severe,  
tube feeds
7 413 381 844 118 Y Normal Moderate Severe Moderate U N Moderate,  
tube feeds
8 29 225 674 95 N Loss Severe Severe Severe U Y Shoulder 
dystocia
Severe,  
tube feeds
9 0 n/a 563 94 Y Equivocal Moderate Mild Moderate U N Moderate,  
tube feeds
10 0 0 511 96 n/a Loss Moderate Mild Normal U N Severe,  
tube feeds
11 0 294 506 100 Y Normal Mild Mild Normal F N Normal
12 681 419 490 18 N Loss Severe Normal Moderate U N Normal
13 141 321 403 115 N Normal Normal Normal Normal F Y Placental 
abruption
Normal
14 99 577 381 67 N Normal Normal Normal Normal F Y Head 
entrapment
Normal
15 28 77 336 101 N Normal Normal Mild Mild F Y Shoulder 
dystocia
Normal
16 173 159 334 101 N Loss Severe Moderate Mild U N Normal
17 277 457 324 62 N Normal Normal Normal Normal F N Mild
18 166 160 242 86 Y Normal Mild Normal Normal F N Normal
19 0 71 164 108 n/a Normal Normal Mild Normal F N Normal
20 148 172 151 48 Y Loss Moderate Severe Normal U N Moderate,  
tube feeds
21 0 41 143 115 n/a Normal Normal Normal Normal F N Normal
22 0 0 136 114 Y Normal Normal Moderate Normal F N Normal
23 0 0 59 102 N Normal Normal Normal Normal F N Normal
24 0 0 8 – n/a Normal Normal Normal Normal F N Normal
25 0 0 0 – Y Normal Normal Mild Mild F N Normal
26 0 0 0 – N Normal Normal Normal Normal F Y Uterine  
rupture
Normal
PLIC, posterior limb of internal capsule; BGT, basal ganglia and thalami; WM, white matter; n/a, sample was not available; F, favorable; U, unfavorable; y, yes; n, no.
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a combination of subcortical WM and BGT abnormalities, five had 
predominantly BGT abnormalities, and two had predominantly 
subcortical WM abnormalities (Table  2). Representative images 
are shown in Figure 1. Overall scores for the MR images of the 
26 babies who underwent TH showed 96% inter-rater agreement.
Perinatal characteristics and nfl levels
Median (IQR) age at obtaining the first sample in the mild HIE 
group was 24 (13, 34)  h (Table  3). Three of the 11 babies in 
this group had a detectable or raised NfL level. Median (IQR) 
NfL levels in this whole group were 0 (0, 41)  pg/mL. In the 
babies who had received TH (n = 26), there was no statistically 
significant correlation between the highest NfL level and 10-min 
Apgar, worst pH, and base deficit in the first hour. Similarly, 
there was no significant correlation between the presence of 
electrographic seizures on amplitude-integrated EEG monitor-
ing and NfL levels.
Plasma nfl levels in babies with 
Unfavorable Outcome compared to the 
Other groups
There was no significant difference between groups in age at 
obtaining samples S1, S2, and S3 (Table  3). Median values 
(IQR) of the three groups at the different time points are shown 
in Table 3. The evolution of NfL levels during cooling for indi-
vidual babies is shown in Figure 2. After log transformation 
and analysis of variance, the difference in initial NfL levels 
between the three groups was highly significant (F =  25.83, 
p < 0.0001).
FigUre 1 | Representative MR images of study babies. (a) Diffuse high T2 
signal throughout the basal ganglia (arrow) from baby 3. (b) Abnormal high 
T1 signal throughout the basal ganglia and thalami as well as complete loss 
of signal in the posterior limb of internal capsule (arrow) also from baby 3. (c) 
Widespread T1 high signal (arrow) in cortex (“cortical highlighting”) from baby 
6. (D) Normal signal throughout the basal ganglia in T2-weighted image from 
baby 23.
Table 3 | The median neurofilament light levels and age after birth of patients in the study.
s1 (pg/ml) age (h) s2 (pg/ml) age (h) s3 (pg/ml) age (h)
Mild
No TH
0 (0, 41) 24 (13, 34) – – – –
Mod-severe
TH favorable
0 (0, 110) 16 (11, 22) 71 (0, 200) 57 (48, 62) 164 (47, 327) 103 (96, 108)
Mod-severe
TH unfavorable
173 (29, 681) 18 (15, 24) 381 (180, 968) 54 (42, 60) 844 (511, 1,014) 96 (95, 104)
Interquartile ranges are expressed in brackets.
TH, therapeutic hypothermia.
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Temporal increase in Plasma nfl level in 
babies Treated with Th
For the babies who underwent TH, sequential NfL levels were 
higher in those with MR-evident brain injury predictive of unfa-
vorable outcome compared to NfL levels in those with MRI pre-
dictive of favorable outcomes (mixed models, two-way ANOVA, 
F = 27.6, p < 0.001) (Figure 3). In both groups, median NfL levels 
increased over the course of TH treatment; initial NfL levels (S1) 
were not only higher in babies with unfavorable outcomes but 
also remained higher throughout the time course, in comparison 
to those from babies with favorable outcomes.
All infants with unfavorable outcomes had some rise in NfL 
levels. All infants with NfL levels >400 pg/mL at the first sample 
(n = 6) had unfavorable outcomes. Of the 13 infants with favora-
ble outcomes, 10 had some rise in NfL levels. Of these 10, four had 
completely normal MR imaging.
Six infants from the whole TH group with raised NfL levels in 
the first sample after reaching target hypothermia temperature 
(S1) showed a decrease in levels by the time of the second sample 
prior to commencing rewarming (S2). Yet all six showed a sub-
sequent rise in NfL levels by the time of the third sample (post 
rewarming, S3).
Diagnostic accuracy of Plasma nfl levels 
in Prediction of Unfavorable Outcome
ROCs were performed to evaluate the diagnostic value of 
plasma NfL levels in predicting MRI predictive of abnormal 
outcome in newborns with HIE. At all three sampling time 
points, NfL cut-off levels likely to be predictive of unfavorable 
outcomes were obtained (Figure 4; Table 3). In babies under-
going TH, an NfL level of >29 pg/ml at S1 was predictive of 
unfavorable outcome, with area under the curve (AUC) of 
0.78, p = 0.017, sensitivity 77%, and specificity 69% (Table 4). 
For S3, an NfL level of >417 pg/mL was strongly predictive of 
unfavorable outcome with AUC 0.97, p <  0.0001, sensitivity 
92%, and specificity 92%. On arranging the subjects in rank 
order of NfL levels at S3, it is notable that babies with higher 
NfL levels were more likely to have cerebral abnormalities 
on MRI (Table 2). However, one newborn with an NFL level 
>417 pg/mL had MRI predictive of favorable outcome and two 
with NFL levels <417 pg/mL had MRI predictive of unfavora-
ble outcomes.
DiscUssiOn
We demonstrate that it is feasible to study NfL levels in plasma 
from newborn babies. In newborns undergoing TH for HIE, NfL 
levels were raised as early as 24 h after birth in those who had 
cerebral MRI predictive of unfavorable neurodevelopmental out-
come. NfL levels rose during the course of TH and were highest 
post rewarming. A cutoff NfL level >417 pg/mL after rewarming 
was strongly predictive of unfavorable outcome. Thus, raised NfL 
levels may be an important biomarker of neuronal, and more 
specifically axonal damage, in this group of babies.
FigUre 2 | Evolution of neurofilament light (NfL) over the three time points in the therapeutic hypothermia groups.
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Although safe, TH does not benefit all babies with HIE (3, 4). 
Long-term follow-up from randomized controlled trials shows 
that up to 50% of babies who underwent TH nevertheless had 
adverse outcomes of death and disability (5, 6). At present, there 
are no clinically established biomarkers of brain injury available 
at the cot side that allow objective selection of babies for existing 
neuroprotective strategies such as TH or for stratifying babies 
for additional, novel interventions. The data from our study 
are consistent with the preliminary findings from Toorell et al. 
(15) and support plasma NfL as being a suitable candidate early 
biomarker worthy of further investigation. Furthermore, serum 
NfL levels have been shown to be raised in adult traumatic brain 
injury (18, 19).
In their study, Toorell et al. (15) compared NfL levels from 
the cord blood of 10 asphyxiated children with that of cord 
blood from 18 controls. Of their 10 cases, seven did not suffer 
FigUre 3 | Temporal changes in plasma neurofilament light (NfL) levels in groups with different severity of brain injury. Data expressed as median with interquartile 
ranges and whiskers with minimum to maximum.
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HIE. In our study, all cases undergoing TH had fulfilled local 
criteria for treatment. Although in this work we did not study 
cord blood, we were able to study the temporal evolution of the 
plasma NfL levels through the TH process and relate the NfL 
levels to MRI outcome. In this study, we did not carry out a 
comparison of a perinatal severity of “sickness” scoring system 
to NfL levels.
We noted that half the babies in the TH group had raised NfL 
levels in the first specimen. We speculate that the insult may have 
occurred some time prior to delivery in some of this group. In six 
Table 4 | Diagnostic power of neurofilament light levels comparing babies newborns with favorable and unfavorable outcomes within the therapeutic hypothermia 
group at samples S1, S2, and S3.
sample area under curve se p Value cutoff (pg/ml) sensitivity (%) specificity (%) PPV (%) nPV (%)
S1 0.775 0.094 0.017 29 77 69 67 73
S2 0.766 0.100 0.028 166 82 69 69 82
S3 0.965 0.032 <0.0001 417 92 92 92 86
PPV, positive predictive value; NPV, negative predictive value.
FigUre 4 | Receiver operated characteristics curves of the neurofilament light (NfL) biomarker in the plasma of newborns with panel (a) representing a comparison 
of NfL level for babies with mild hypoxic-ischemic encephalopathy (HIE) [no therapeutic hypothermia (TH)] with TH babies with unfavorable outcome for the first 
sample and panels (b–D) representing a comparison of babies who had undergone TH at samples 1 (b), sample 2 (c), and sample 3 (D).
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of all the babies who received TH with raised NfL levels in the 
first specimen, there was a drop in NfL level noted in the second 
sample with the baby still being cooled. However, in all six, a 
rise in NfL levels was noted after rewarming was complete. This 
may be an observed effect of TH; a better understanding of the 
temporal changes in plasma NfL levels may also allow for more 
precise timing of the occurrence of the hypoxic-ischemic insult 
as well as better monitoring of the response to neuroprotective 
treatments.
To date, various blood-detected molecules have been pro-
posed as potential biomarkers of brain injury after HIE (8). 
However, many of these markers are not specific to brain injury. 
One potential advantage of neurofilaments as biomarkers in the 
newborn is that they are neuron-specific cytoskeletal proteins, 
released into the CSF and blood when neurons are damaged (10). 
In this work, we have investigated only the NfL subunit because 
researchers from our institution and others have shown that NfL 
levels are raised in neurologic conditions in which neuronal and 
particularly axonal injury is important (11–13). Further work is 
required to test the utility of the other neurofilament subunits as 
potential biomarkers.
We used a commercially available sandwich ELISA kit that 
uses a heterophilic antibody designed for detecting NfL levels in 
the CSF, with a lower detection limit of 32 pg/mL. At present, this 
test can be carried out and results obtained within 3 h. We were 
able to show a significant difference between the groups in rela-
tion to cerebral injury on MRI, as well as a function of time. This 
antibody has been used in other studies on plasma and serum, 
albeit with other platforms (12). The newborns with unfavorable 
outcomes in this study had NfL levels (median 792 pg/mL) that 
were higher than those observed in the plasma from adults with 
ALS (median 96 pg/mL) (11). We postulate that this difference 
relates to the time course of the insult in newborns being more 
acute and the nature of the insult more global, compared to the 
more focal and chronic, slow-developing nature of the pathol-
ogy in ALS.
A limitation of our study is that we did not have plasma 
specimens from cord blood, or from the babies before cooling 
was commenced. Also, we do not have samples from infants with 
moderate–severe HIE who did not receive TH. Although longer 
term neurodevelopmental outcomes are as yet unavailable, the 
method of scoring the MRIs that we used has been shown to be 
predictive of longer term outcomes (17).
cOnclUsiOn
Our data suggest that plasma NfL is a potentially useful 
biomarker for predicting unfavorable MRI outcomes in 
newborns with moderate–severe HIE undergoing TH. As a 
biomarker at 24  h of age and beyond, NfL levels may be of 
value for adjunctive neuroprotective treatments targeting the 
reperfusion and “repair” phases after hypoxia-ischemia. A 
larger study is required to confirm our findings, and should 
include plasma specimens from within the first 6 h after birth 
and explore the potential additional utility of intermediate 
and heavy subunits of neurofilaments. Further work is also 
required to correlate NfL levels with longer term neurodevel-
opmental outcomes.
WhaT is KnOWn abOUT This TOPic?
 – Therapeutic hypothermia does not benefit all newborns after 
hypoxic-ischemic encephalopathy
 – There are no blood biomarkers that allow selection of babies 
for neuroprotection at present
 – Neurofilament light (NfL) chains have been shown to be 
raised in blood and CSF from patients with other neuro-
logical pathology as well as cord blood from babies with 
asphyxia
WhaT This sTUDY aDDs
 – It is feasible to measure NfL levels, a marker of axonal injury, 
in the plasma of newborns
 – NfL levels are raised at 24 h in newborns undergoing thera-
peutic hypothermia with cerebral tissue injury predictive of 
unfavorable outcome
 – NfL levels may allow stratification of newborns to adjunctive 
brain saving treatments
eThics sTaTeMenT
This study was carried out in accordance with the recommenda-
tions of Bromley Research Ethics Committee with written informed 
consent from all parents. All parents gave written informed con-
sent in accordance with the Declaration of Helsinki. The protocol 
was approved by the Bromley Research Ethics Committee.
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